Biogen Stock Declines 20.9% Year to Date: Time to Sell?
ZacksBIIB’s reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.
BIIB’s reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.